Design and methodology of the NorthStar Study: NT-proBNP stratified follow-up in outpatient heart failure clinics -- a randomized Danish multicenter study

Morten Schou, Finn Gustafsson, Lars Videbaek, John Markenvard, Hans Ulriksen, Henrik Ryde, Jens C H Jensen, Tonny Nielsen, Anne S Knudsen, Christian D Tuxen, Jens Handberg, Per J Sørensen, Geert Espersen, Søren Lind-Rasmussen, Niels Keller, Kenneth Egstrup, Olav W Nielsen, Jawdat Abdulla, Ole Nyvad, Jens Toft & 1 andre Per R Hildebrandt

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Udgivelsesdato: 2008-Oct
OriginalsprogEngelsk
TidsskriftAmerican Heart Journal
Vol/bind156
Udgave nummer4
Sider (fra-til)649-55
Antal sider6
ISSN0002-8703
StatusUdgivet - 1. okt. 2008

Fingeraftryk

Brain Natriuretic Peptide
Multicenter Studies
Outpatients
Natriuretic Peptides
Physiologic Monitoring
Denmark
General Practice
Randomized Controlled Trials
Nurses

Citer dette

Schou, M., Gustafsson, F., Videbaek, L., Markenvard, J., Ulriksen, H., Ryde, H., ... Hildebrandt, P. R. (2008). Design and methodology of the NorthStar Study: NT-proBNP stratified follow-up in outpatient heart failure clinics -- a randomized Danish multicenter study. American Heart Journal, 156(4), 649-55.
Schou, Morten ; Gustafsson, Finn ; Videbaek, Lars ; Markenvard, John ; Ulriksen, Hans ; Ryde, Henrik ; Jensen, Jens C H ; Nielsen, Tonny ; Knudsen, Anne S ; Tuxen, Christian D ; Handberg, Jens ; Sørensen, Per J ; Espersen, Geert ; Lind-Rasmussen, Søren ; Keller, Niels ; Egstrup, Kenneth ; Nielsen, Olav W ; Abdulla, Jawdat ; Nyvad, Ole ; Toft, Jens ; Hildebrandt, Per R. / Design and methodology of the NorthStar Study: NT-proBNP stratified follow-up in outpatient heart failure clinics -- a randomized Danish multicenter study. I: American Heart Journal. 2008 ; Bind 156, Nr. 4. s. 649-55.
@article{a73a15d0acb611dd9b31000ea68e967b,
title = "Design and methodology of the NorthStar Study: NT-proBNP stratified follow-up in outpatient heart failure clinics -- a randomized Danish multicenter study",
abstract = "BACKGROUND: Randomized clinical trials have shown that newly discharged and symptomatic patients with chronic heart failure (CHF) benefit from follow-up in a specialized heart failure clinic (HFC). Clinical stable and educated patients are usually discharged from the HFC when on optimal therapy. It is unknown if risk stratification using natriuretic peptides could identify patients who would benefit from longer-term follow-up. Furthermore, data on the use of natriuretic peptides for monitoring of stable patients with CHF are sparse. AIMS: The aims of this study are to test the hypothesis that clinical stable, educated, and medical optimized patients with CHF with N-terminal pro-brain natriuretic peptide (NT-proBNP) levels > or = 1,000 pg/mL benefit from long-term follow-up in an HFC and to assess the efficacy of NT-proBNP monitoring. METHODS: A total of 1,250 clinically stable, medically optimized, and educated patients with CHF will be enrolled from 18 HFCs in Denmark. The patients will be randomized to treatment in general practice, to a standard follow-up program in the HFC, or to NT-proBNP monitoring in the HFC. The patients will be followed for 30 months (median). RESULTS: Data will be collected from 2006 to 2009. At present (March 2008), 720 patients are randomized. Results expect to be presented in the second half of 2010. CONCLUSIONS: This article outlines the design of the NorthStar study. If our hypotheses are confirmed, the results will help cardiologists and nurses in HFCs to identify patients who may benefit from long-term follow-up. Our results may also indicate whether patients with CHF will benefit from adding serial NT-proBNP measurements to usual clinical monitoring.",
author = "Morten Schou and Finn Gustafsson and Lars Videbaek and John Markenvard and Hans Ulriksen and Henrik Ryde and Jensen, {Jens C H} and Tonny Nielsen and Knudsen, {Anne S} and Tuxen, {Christian D} and Jens Handberg and S{\o}rensen, {Per J} and Geert Espersen and S{\o}ren Lind-Rasmussen and Niels Keller and Kenneth Egstrup and Nielsen, {Olav W} and Jawdat Abdulla and Ole Nyvad and Jens Toft and Hildebrandt, {Per R}",
year = "2008",
month = "10",
day = "1",
language = "English",
volume = "156",
pages = "649--55",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby, Inc.",
number = "4",

}

Schou, M, Gustafsson, F, Videbaek, L, Markenvard, J, Ulriksen, H, Ryde, H, Jensen, JCH, Nielsen, T, Knudsen, AS, Tuxen, CD, Handberg, J, Sørensen, PJ, Espersen, G, Lind-Rasmussen, S, Keller, N, Egstrup, K, Nielsen, OW, Abdulla, J, Nyvad, O, Toft, J & Hildebrandt, PR 2008, 'Design and methodology of the NorthStar Study: NT-proBNP stratified follow-up in outpatient heart failure clinics -- a randomized Danish multicenter study', American Heart Journal, bind 156, nr. 4, s. 649-55.

Design and methodology of the NorthStar Study: NT-proBNP stratified follow-up in outpatient heart failure clinics -- a randomized Danish multicenter study. / Schou, Morten; Gustafsson, Finn; Videbaek, Lars; Markenvard, John; Ulriksen, Hans; Ryde, Henrik; Jensen, Jens C H; Nielsen, Tonny; Knudsen, Anne S; Tuxen, Christian D; Handberg, Jens; Sørensen, Per J; Espersen, Geert; Lind-Rasmussen, Søren; Keller, Niels; Egstrup, Kenneth; Nielsen, Olav W; Abdulla, Jawdat; Nyvad, Ole; Toft, Jens; Hildebrandt, Per R.

I: American Heart Journal, Bind 156, Nr. 4, 01.10.2008, s. 649-55.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Design and methodology of the NorthStar Study: NT-proBNP stratified follow-up in outpatient heart failure clinics -- a randomized Danish multicenter study

AU - Schou, Morten

AU - Gustafsson, Finn

AU - Videbaek, Lars

AU - Markenvard, John

AU - Ulriksen, Hans

AU - Ryde, Henrik

AU - Jensen, Jens C H

AU - Nielsen, Tonny

AU - Knudsen, Anne S

AU - Tuxen, Christian D

AU - Handberg, Jens

AU - Sørensen, Per J

AU - Espersen, Geert

AU - Lind-Rasmussen, Søren

AU - Keller, Niels

AU - Egstrup, Kenneth

AU - Nielsen, Olav W

AU - Abdulla, Jawdat

AU - Nyvad, Ole

AU - Toft, Jens

AU - Hildebrandt, Per R

PY - 2008/10/1

Y1 - 2008/10/1

N2 - BACKGROUND: Randomized clinical trials have shown that newly discharged and symptomatic patients with chronic heart failure (CHF) benefit from follow-up in a specialized heart failure clinic (HFC). Clinical stable and educated patients are usually discharged from the HFC when on optimal therapy. It is unknown if risk stratification using natriuretic peptides could identify patients who would benefit from longer-term follow-up. Furthermore, data on the use of natriuretic peptides for monitoring of stable patients with CHF are sparse. AIMS: The aims of this study are to test the hypothesis that clinical stable, educated, and medical optimized patients with CHF with N-terminal pro-brain natriuretic peptide (NT-proBNP) levels > or = 1,000 pg/mL benefit from long-term follow-up in an HFC and to assess the efficacy of NT-proBNP monitoring. METHODS: A total of 1,250 clinically stable, medically optimized, and educated patients with CHF will be enrolled from 18 HFCs in Denmark. The patients will be randomized to treatment in general practice, to a standard follow-up program in the HFC, or to NT-proBNP monitoring in the HFC. The patients will be followed for 30 months (median). RESULTS: Data will be collected from 2006 to 2009. At present (March 2008), 720 patients are randomized. Results expect to be presented in the second half of 2010. CONCLUSIONS: This article outlines the design of the NorthStar study. If our hypotheses are confirmed, the results will help cardiologists and nurses in HFCs to identify patients who may benefit from long-term follow-up. Our results may also indicate whether patients with CHF will benefit from adding serial NT-proBNP measurements to usual clinical monitoring.

AB - BACKGROUND: Randomized clinical trials have shown that newly discharged and symptomatic patients with chronic heart failure (CHF) benefit from follow-up in a specialized heart failure clinic (HFC). Clinical stable and educated patients are usually discharged from the HFC when on optimal therapy. It is unknown if risk stratification using natriuretic peptides could identify patients who would benefit from longer-term follow-up. Furthermore, data on the use of natriuretic peptides for monitoring of stable patients with CHF are sparse. AIMS: The aims of this study are to test the hypothesis that clinical stable, educated, and medical optimized patients with CHF with N-terminal pro-brain natriuretic peptide (NT-proBNP) levels > or = 1,000 pg/mL benefit from long-term follow-up in an HFC and to assess the efficacy of NT-proBNP monitoring. METHODS: A total of 1,250 clinically stable, medically optimized, and educated patients with CHF will be enrolled from 18 HFCs in Denmark. The patients will be randomized to treatment in general practice, to a standard follow-up program in the HFC, or to NT-proBNP monitoring in the HFC. The patients will be followed for 30 months (median). RESULTS: Data will be collected from 2006 to 2009. At present (March 2008), 720 patients are randomized. Results expect to be presented in the second half of 2010. CONCLUSIONS: This article outlines the design of the NorthStar study. If our hypotheses are confirmed, the results will help cardiologists and nurses in HFCs to identify patients who may benefit from long-term follow-up. Our results may also indicate whether patients with CHF will benefit from adding serial NT-proBNP measurements to usual clinical monitoring.

M3 - Journal article

VL - 156

SP - 649

EP - 655

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 4

ER -